The effectiveness and safety of the use of antithrombotic therapy in COVID-19

The article is a non-systematic review of the literature, addressing the effectiveness, safety and appropriateness of antithrombotic drugs for COVID-19 in patients undergoing treatment in different settings: in the hospital phase, including the intensive care unit, in the outpatient phase after discharge from hospital, in primary outpatient treatment. The issues of thrombotic complications during vaccination and the necessity of their prevention are discussed. The studies confirm the importance of prophylactic doses of anticoagulants in all hospitalized patients. The use of increased doses has proven ineffective in patients with a severe course of the disease who are being treated in the intensive care unit. In moderately severe infections, there is a clear benefit of increased doses of anticoagulants in reducing the risk of organ failure, but definitive conclusions can only be drawn after the final results of the studies have been published. Prolonged pharmacological prophylaxis after hospital discharge may be useful in individual patients, but the overall risk of thrombotic complications in the long-term period does not appear to be high. The available data do not support the use of anticoagulants in the treatment of coronavirus disease in the outpatient settings, since the risk of thrombotic complications is not increased in such patients, and the safety of anticoagulant use has not been evaluated. Sulodexide may be useful in selected outpatients at increased risk of disease progression. Vaccination may provoke the development of atypical localized thrombosis by immune mechanisms, but the risk of such complications is lower in the coronavirus disease itself. Anticoagulant prophylaxis during vaccine administration is not indicated.

1. Lobastov K.V., Schastlivtsev I.V., Porembskaya O.Ya., Dzenina O.V., Bargandzhiya A.B., Tsaplin S.N. COVID-19- Associated Coagulopathy: Review of Current Recommendations for Diagnosis, Treatment and Prevention. Ambulatornaya khirurgiya = Ambulatory Surgery (Russia). 2020. (In Russ.) https://doi.org/10.21518/1995-1477-2020-3-4.

2. Malas M.B., Naazie I.N., Elsayed N., Mathlouthi A., Marmor R., Clary B. Thromboembolism Risk of COVID-19 Is High and Associated with a Higher Risk of Mortality: A Systematic Review and Meta-Analysis. EClinicalMedicine. 2020;29:100639. https://doi.org/10.1016/j.eclinm.2020.100639.

3. Jimenez D., Garcia-Sanchez A., Rali P., Muriel A., Bikdeli B., Ruiz-Artacho P. et al. Incidence of VTE and Bleeding among Hospitalized Patients with Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest. 2021;159(3):1182–1196. https://doi.org/10.1016/j.chest.2020.11.005.

4. Zeng D.X., Xu J.L., Mao Q.X., Liu R., Zhang W.Y., Qian H.Y., Xu L. Association of Padua Prediction Score with In-Hospital Prognosis in COVID-19 Patients. QJM. 2020;113(11):789–793. https://doi.org/10.1093/qjmed/hcaa224.

5. Tsaplin S., Schastlivtsev I., Zhuravlev S., Barinov V., Lobastov K., Caprini J.A. The Original and Modified Caprini Score Equally Predicts Venous Thromboembolism in COVID-19 Patients. J Vasc Surg Venous Lymphat Disord. 2021;S2213-333X(21)00105-0. https://doi.org/10.1016/j.jvsv.2021.02.018.

6. Lobastov K.V., Barinov V.E., Schastlivtsev I.V., Laberko L.A. Caprini score as individual risk assessment model of postoperative venous thromboembolism in patients with high surgical risk. Khirurgiya. Zhurnal im. N.I. Pirogova = Pirogov Russian Journal of Surgery. 2014;(12):16–23. (In Russ.) Available at: https://mediasphera.ru/issues/khirurgiyazhurnal-im-n-i-pirogova/2014/12/030023-12072014123.

7. Spyropoulos A.C., Cohen S.L., Gianos E., Kohn N., Giannis D., Chatterjee S. et al. Validation of the IMPROVE-DD Risk Assessment Model for Venous Thromboembolism among Hospitalized Patients with COVID-19. Res Pract Thromb Haemost. 2021;5(2):296–300. https://doi.org/10.1002/rth2.12486.

8. Tang N., Bai H., Chen X., Gong J., Li, D., Sun Z. Anticoagulant Treatment Is Associated with Decreased Mortality in Severe Coronavirus Disease 2019 Patients with Coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099. https://doi.org/10.1111/jth.14817.

9. Leentjens J., van Haaps T.F., Wessels P.F., Schutgens R.E. G., Middeldorp S. COVID-19-Associated Coagulopathy and Antithrombotic Agents-Lessons after 1 Year. Lancet Haematol. 2021:S2352-3026(21)00105-8. https://doi.org/10.1016/S2352-3026(21)00105-8.

10. Paranjpe I., Fuster V., Lala A., Russak A.J., Glicksberg B.S., Levin M.A. et al. Association of Treatment Dose Anticoagulation with In-Hospital Survival among Hospitalized Patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122–124. https://doi.org/10.1016/j.jacc.2020.05.001.

11. Nadkarni G.N., Lala A., Bagiella E., Chang H.L., Moreno P.R., Pujadas E. et al. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients with COVID-19. J Am Coll Cardiol. 2020;76(16):18(2)5–1826. https://doi.org/10.1016/j.thromres.2020.09.033.

12. Ayerbe L., Risco C., Ayis S., The Association between Treatment with Heparin and Survival in Patients with Covid-19. J Thromb Thrombolysis. 2020;50(2):298–301. https://doi.org/10.1007/s11239-020-02162-z.

13. Poulakou G., Dimakakos E., Kollias A., Kyriakoulis K.G., Rapti V., Trontzas I. et al. Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study. In Vivo. 2021;35(1):653–661. https://doi.org/10.21873/invivo.12305.

14. Tassiopoulos A.K., Mofakham S., Rubano J.A., Labropoulos N., Bannazadeh M., Drakos P. et al. D-Dimer-Driven Anticoagulation Reduces Mortality in Intubated COVID-19 Patients: A Cohort Study With a Propensity-Matched Analysis. Front Med (Lausanne). 2021;8:631335. https://doi.org/10.3389/fmed.2021.631335.

15. Chocron R., Galand V., Cellier J., Gendron N., Pommier T., Bory O. et al. Anticoagulation before Hospitalization Is a Potential Protective Factor for COVID-19: Insight from a French Multicenter Cohort Study. J Am Heart Assoc. 2021;10(8):e018624. https://doi.org/10.1161/JAHA.120.018624.

16. Lynn L., Reyes J.A., Hawkins K., Panda A., Linville L., Aldhahri W. et al. The Effect of Anticoagulation on Clinical Outcomes in Novel Coronavirus (COVID-19) Pneumonia in a U.S. Cohort. Thromb Res. 2021;197:65–68. https://doi.org/10.1016/j.thromres.2020.10.031.

17. Meizlish M.L., Goshua G., Liu Y., Fine R., Amin K., Chang E. et al. Intermediate-Dose Anticoagulation, Aspirin, and In-Hospital Mortality in COVID-19: A Propensity Score-Matched Analysis. Am J Hematol. 2021;96(4):471–479. https://doi.org/10.1002/ajh.26102.

18. Chow J.H., Khanna A.K., Kethireddy S., Yamane D., Levine A., Jackson A.M. et al. Aspirin Use Is Associated with Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients with Coronavirus Disease 2019. Anesth Analg. 2021;132(4):930–941. https://doi.org/10.1213/ane.0000000000005292.

19. Kessler C., Stricker H., Demundo D., Elzi L., Monotti R., Bianchi G. et al. Bleeding Prevalence in COVID-19 Patients Receiving Intensive Antithrombotic Prophylaxis. J Thromb Thrombolysis. 2020;50(4):833–836. https://doi.org/10.1007/s11239-020-02244-y.

20. Musoke N., Lo K.B., Albano J., Peterson E., Bhargav R., Gul F. et al. Anticoagulation and Bleeding Risk in Patients with COVID-19. Thromb Res. 2020;196:227–230. https://doi.org/10.1016/j.thromres.2020.08.035.

21. Pesavento R., Ceccato D., Pasquetto G., Monticelli J., Leone L., Frigo A. et al. The Hazard of (Sub)Therapeutic Doses of Anticoagulants in Non-Critically Ill Patients with Covid-19: The Padua Province Experience. J Thromb Haemost. 2020;18(10):2629–2635. https://doi.org/10.1111/jth.15022.

22. Parisi R., Costanzo S., Di Castelnuovo A., de Gaetano G., Donati M.B., Iacoviello L. Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis. Semin Thromb Hemost. 2021;47(4):372–391. https://doi.org/1055/s-0041-1726034.

23. Lemos A.C. B., do Espirito Santo D.A., Salvetti M.C., Gilio R.N., Agra L.B., Pazin-Filho A., Miranda C.H. Therapeutic versus Prophylactic Anticoagulation for Severe COVID-19: A Randomized Phase II Clinical Trial (HESACOVID). Thromb Res. 2020;196:359–366. https://doi.org/10.1016/j.thromres.2020.09.026.

24. Sadeghipour P., Talasaz A.H., Rashidi F., Sharif-Kashani B., Beigmohammadi M.T., Farrokhpour M. et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality among Patients with COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021;325(16):1620–1630. https://doi.org/10.1001/jama.2021.4152.

25. Zarychanski R. Therapeutic Anticoagulation in Critically Ill Patients with Covid-19 – Preliminary Report. medRxiv. 2021;03.10.21252749. https://doi.org/10.1101/2021.03.10.21252749.

26. Schultz N.H., Sørvoll I.H., Michelsen A.E., Munthe L.A., Lund-Johansen F., Ahlen M.T. et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021;384(22):2124–2130. https://doi.org/10.1056/nejmoa2104882.

27. Roberts L.N., Whyte M.B., Georgiou L., Giron G., Czuprynska J., Rea C. et al. Postdischarge Venous Thromboembolism Following Hospital Admission with COVID-19. Blood. 2020;136(11):1347–1350. https://doi.org/10.1182/blood.2020008086.

28. Patell R., Bogue T., Koshy A., Bindal P., Merrill M., Aird W.C. et al. Postdischarge Thrombosis and Hemorrhage in Patients with COVID-19. Blood. 2020;136(11):1342–1346. https://doi.org/10.1182/blood.2020007938.

29. Bourguignon A., Beaulieu C., Belkaid W., Desilets A., Blais N. Incidence of Thrombotic Outcomes for Patients Hospitalized and Discharged after COVID-19 Infection. Thromb Res. 2020;196:491–493. https://doi.org/10.1016/j.thromres.2020.10.017.

30. Engelen M.M., Vandenbriele C., Balthazar T., Claeys E., Gunst J., Guler I. et al. Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization. Res Pract Thromb Haemost. 2020;4(5):842–847. https://doi.org/10.1002/rth2.12376.

31. Gianni D., Allen S., Tsang J., Flint S., Pinhasov T., Williams S. et al. Postdischarge Thromboembolic Outcomes and Mortality of Hospitalized COVID-19 Patients: The CORE-19 Registry. Blood. 2021;137(20):2838–2847. https://doi.org/10.1182/blood.2020010529.

32. Al-Aly Z., Xie Y., Bowe B. High-Dimensional Characterization of Post-Acute Sequalae of COVID-19. Nature. 2021;594(7862): 259–264. https://doi.org/10.1038/s41586-021-03553-9.

33. Dalager-Pedersen M., Lund L.C., Mariager T., Winther R., Hellfritzsch M., Larsen T.B. et al. Venous Thromboembolism and Major Bleeding in Patients with COVID-19: A Nationwide Population-Based Cohort Study. Clin Infect Dis. 2021;ciab003. https://doi.org/10.1093/cid/ciab003.

34. Lund L.C., Hallas J., Nielsen H., Koch A., Mogensen S.H., Brun N.C. et al. Post-Acute Effects of SARS-CoV-2 Infection in Individuals Not Requiring Hospital Admission: A Danish Population-Based Cohort Study. Lancet Infect Dis. 2021;S1473-3099(21)00211-5. https://doi.org/10.1016/s1473-3099(21)00211-5.

35. Roubinian N.H., Dusendang J.R., Mark D.G., Vinson D.R., Liu V.X., Schmittdiel J.A., Pai A.P. Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California. JAMA Intern Med. 2021:e210488. https://doi.org/10.1001/jamainternmed.2021.0488.

36. Flam B., Wintzell V., Ludvigsson J.F., Martensson J., Pasternak B. Direct Oral Anticoagulant Use and Risk of Severe COVID-19. J Intern Med. 2021;289(3):411–419. https://doi.org/10.1111/joim.13205.

37. Gonzalez Ochoa A.J., Raffetto J., Hernandez Ibarra A.G., Zavala N., Gutierrez O., Vargas A., Loustaunau J. Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial. Thromb Haemost. 2021. https://doi.org/10.1055/a-1414-5216.

38. Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021;384(22):2092–2101. https://doi.org/10.1056/nejmoa2104840.

39. Scully M., Singh D., Lown R., Poles A., Solomon T., Levi M. et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021;384(23):2202–2211. https://doi.org/10.1056/nejmoa2105385.

40. Cines D.B., Bussel J.B. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med. 2021;384(23):2254–2256. https://doi.org/10.1056/nejme2106315.

41. Oldenburg J., Klamroth R., Langer F., Albisetti M., von Auer C., Ay C. et al. Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH. Hamostaseologie. 2021. https://doi.org/10.1055/a-1469-7481.

42. Taquet M., Husain M., Geddes J.R., Luciano S., Harrison P.J. Cerebral Venous Thrombosis and Portal Vein Thrombosis: A Retrospective Cohort Study of 537,913 COVID-19 Cases. medRxiv. 2021;04.27.21256153. https://doi.org/10.1101/2021.04.27.21256153.

43. Szolnoky G. Sulodexide may be a real alternative to low molecular weight heparins in the prevention of COVID-19 induced vascular complications. Dermatol Ther. 2020;33(6):e14437.https://doi.org/10.1111/dth.14437.